South Korea Crispr And Cas Genes Market Size & Outlook
The crispr and cas genes market in South Korea is expected to reach a projected revenue of US$ 304.5 million by 2030. A compound annual growth rate of 15.6% is expected of South Korea crispr and cas genes market from 2025 to 2030.
Revenue, 2024 (US$M)
$128.9
Forecast, 2030 (US$M)
$304.5
CAGR, 2025 - 2030
15.6%
Report Coverage
South Korea
Related Markets
South Korea crispr and cas genes market highlights
- The South Korea crispr and cas genes market generated a revenue of USD 128.9 million in 2024 and is expected to reach USD 304.5 million by 2030.
- The South Korea market is expected to grow at a CAGR of 15.6% from 2025 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2024.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
Crispr and cas genes market data book summary
| Market revenue in 2024 | USD 128.9 million |
| Market revenue in 2030 | USD 304.5 million |
| Growth rate | 15.6% (CAGR from 2025 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
Other key industry trends
- In terms of revenue, South Korea accounted for 2.8% of the global crispr and cas genes market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China crispr and cas genes market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,162.8 million by 2030.
Product was the largest segment with a revenue share of 87.43% in 2024. Horizon Databook has segmented the South Korea crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea’s CRISPR market is expected to be driven by strategic developments of local players. Tool Gen, Inc., one of the major players in South Korea’s CRISPR market, has undertaken multiple licensing agreements and collaborations with international companies to expand the use of its CRISPR/Cas9 technologies.
For instance, in August 2019, Tool Gen collaborated with Viva Zome Therapeutics Pty Ltd., a privately held Australian biotech company, to explore gene editing of cells for improved production of exosome s. Tool Gen employed its CRISPR/Cas9 technology to develop gene edits into selected cell types, which were further analyzed by Viva Zone.
In August 2017, Tool Gen and Monsanto Company, a U.S.-based firm, entered into a licensing agreement, under which the former’s CRISPR technology platform was utilized for development of agricultural products.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
CRISPR And Cas Genes Market Scope
Crispr and cas genes market segmentation & scope
Others
Others
Others
Others
Others
CRISPR And Cas Genes Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Recombinetics | View profile | 11-50 | Eagan, Minnesota, United States, North America | https://recombinetics.com/ |
| Origene Technologies | View profile | 501-1000 | Rockville, Maryland, United States, North America | http://www.origene.com |
| Hera Biotech | View profile | 1-10 | San Antonio, Texas, United States, North America | http://herabiotech.com/ |
| PLANTEDIT | View profile | 51-100 | Cork, Cork, Ireland, Europe | http://plantedit.com/ |
| Inscripta | View profile | 51-100 | Pleasanton, California, United States, North America | https://www.inscripta.com |
| Mammoth Biosciences | View profile | 101-250 | San Francisco, California, United States, North America | https://mammoth.bio/ |
| Synthego | View profile | 251-500 | Redwood City, California, United States, North America | http://www.synthego.com |
| EGenesis | View profile | 101-250 | Cambridge, Massachusetts, United States, North America | https://www.egenesisbio.com/ |
| Addgene | View profile | 11-50 | Cambridge, Massachusetts, United States, North America | http://www.addgene.org/ |
| Vertex Pharmaceuticals Inc | View profile | 5400 | 50 Northern Avenue, Boston, MA, United States, 02210 | https://www.vrtx.com |
| Beam Therapeutics Inc | View profile | 436 | 238 Main Street, Cambridge, MA, United States, 02142 | https://www.beamtx.com |
| Cibus Inc Ordinary Shares - Class A | View profile | 183 | 6455 Nancy Ridge Drive, San Diego, CA, United States, 92121 | https://www.cibus.com |
| Intellia Therapeutics Inc | View profile | 598 | 40 Erie Street, Suite 130, Cambridge, MA, United States, 02139 | https://www.intelliatx.com |
| Editas Medicine Inc | View profile | 226 | 11 Hurley Street, Cambridge, MA, United States, 02141 | https://www.editasmedicine.com |
| CRISPR Therapeutics AG | View profile | 407 | Baarerstrasse 14, Zug, Switzerland, CH-6300 | https://www.crisprtx.com |
| Cellectis SA | View profile | 216 | 8, rue de la Croix Jarry, Paris, France, 75013 | https://www.cellectis.com |
| Genscript Biotech Corp Class H | View profile | 6937 | No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, China, People's Republic of, 211100 | https://www.genscript.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| PerkinElmer | View profile | 10001+ | Waltham, Massachusetts, United States, North America | http://www.perkinelmer.com |
| Caribou Biosciences Inc Ordinary Shares | View profile | 137 | 2929 7th Street, Suite 105, Berkeley, CA, United States, 94710 | https://www.cariboubio.com |
| Takara Bio Inc | View profile | 1793 | Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, Japan, 520-0058 | http://www.takara-bio.co.jp |
| Danaher Corp | View profile | 63000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | https://www.danaher.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
South Korea crispr and cas genes market size, by end use, 2018-2030 (US$M)
South Korea CRISPR And Cas Genes Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
